Antibodies that Inhibit Malaria Merozoite Surface Protein–1 Processing and Erythrocyte Invasion Are Blocked by Naturally Acquired Human Antibodies
Open accessThe DOI matches its Crossref record.
Abstract
Merozoite surface protein–1 (MSP-1) of the human malaria parasite Plasmodium falciparum undergoes at least two endoproteolytic cleavage events during merozoite maturation and release, and erythrocyte invasion. We have previously demonstrated that mAbs which inhibit erythrocyte invasion and are specific for epitopes within a membrane-proximal, COOH-terminal domain of MSP-1 (MSP-119) prevent the critical secondary processing step which occurs on the surface of the extracellular merozoite at around the time of erythrocyte invasion. Certain other anti–MSP-119 mAbs, which themselves inhibit neither erythrocyte invasion nor MSP-1 secondary processing, block the processing-inhibitory activity of the first group of antibodies and are termed blocking antibodies. We have now directly quantitated antibody-mediated inhibition of MSP-1 secondary processing and invasion, and the effects on this of blocking antibodies. We show that blocking antibodies function by competing with the binding of processing-inhibitory antibodies to their epitopes on the merozoite. Polyclonal rabbit antibodies specific for certain MSP-1 sequences outside of MSP-119 also act as blocking antibodies. Most significantly, affinity-purified, naturally acquired human antibodies specific for epitopes within the NH2-terminal 83-kD domain of MSP-1 very effectively block the processing-inhibitory activity of the anti-MSP-119 mAb 12.8. The presence of these blocking antibodies also completely abrogates the inhibitory effect of mAb 12.8 on erythrocyte invasion by the parasite in vitro. Blocking antibodies therefore (a) are part of the human response to malarial infection; (b) can be induced by MSP-1 structures unrelated to the MSP-119 target of processing-inhibitory antibodies; and (c) have the potential to abolish protection mediated by anti–MSP-119 antibodies. Our results suggest that an effective MSP-119–based falciparum malaria vaccine should aim to induce an antibody response that prevents MSP-1 processing on the merozoite surface.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The pathogenic basis of malaria
Miller, L. H., Baruch, D. I., Marsh, K., & Doumbo, O. K. (2002) · Nature · doi:10.1038/415673a · Cited by 1,746
Global analysis of transcript and protein levels across the Plasmodium falciparum life cycle
Le Roch, K. G., Johnson, J. R., Florens, L., Zhou, Y., Santrosyan, A., Grainger, M., Yan, S. F., Williamson, K. C., Holder, A. A., Carucci, D. J., et al. (2004) · Genome Research · doi:10.1101/gr.2523904 · Cited by 447
Self-citationImmune effector mechanisms in malaria
MARSH, K., & KINYANJUI, S. (2006) · Parasite Immunology · doi:10.1111/j.1365-3024.2006.00808.x · Cited by 419
ARTAVANIS-TSAKONAS, K., TONGREN, J. E., & RILEY, E. M. (2003) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2003.02174.x · Cited by 369
Ogutu, B. R., Apollo, O. J., McKinney, D., Okoth, W., Siangla, J., Dubovsky, F., Tucker, K., Waitumbi, J. N., Diggs, C., Wittes, J., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004708 · Cited by 343
Ferguson, N., Anderson, R., & Gupta, S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.2.790 · Cited by 304
O'Donnell, R. A., de Koning-Ward, T. F., Burt, R. A., Bockarie, M., Reeder, J. C., Cowman, A. F., & Crabb, B. S. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.12.1403 · Cited by 270
Antibody-based therapies for malaria
Pleass, R. J., & Holder, A. A. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1267 · Cited by 182
Self-citation
Metadata
- Authors
- Guevara Patiño, J. A., Holder, A. A., McBride, J. S., & Blackman, M. J.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1997-11-17
- Volume
- 186
- Issue
- 10
- Pages
- 1689-1699
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2089035318
- Cited by
- 226
- References
- 0
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.